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Summary.-The blastogenic response to a crude cell extract of ovarian cancer cells
has been studied in 48 patients with ovarian cancer (9, autologous, 39 allogeneic), in
26 female controls matched for age and in 18 female patients with other types of
cancer in remission from disease. The responses in ovarian cancer patients in
remission and relapse were considered separately. The blastogenic responses to
cell extracts offoetal ovary, foetal lung, foetal liver and normal adult ovary were also
assessed in a proportion of all 3 groups.
The blastogenic responses to ovarian cancer and foetal ovary cell extracts were
found to be significantly greater in the ovarian cancer patients in remission than in
the controls, but the responses to ovarian cancer extract were not greater in the
relapse group or in patients with other cancers. As a blastogenic response to normal
ovarian extract was also present in some of these patients, the data so far do not
support the hypothesis of a tumour specific antigen. This tumour associated
response may be occurring to determinants in foetal or adult ovarian tissue to which
the patient becomes sensitized in malignant disease. The response is complex and
the nature of the antigen requires further analysis.
AN IMMUNE response which appears to
be directed towards tumour antigens has
been demonstrated in vitro for several
human tissues (Hellstrom et al., 1971).
Attention in recent years has been
centred on the cell mediated immune
response to tumours and this response
appears to be instrumental in facilitating
tumour rejection (Burnet, 1968).
Cultured peripheral lymphocytes will
transform into lymphoblasts when chall-
enged in vitro by an antigen to which
the host has previously been sensitized
(Coulson and Chalmers, 1967; Bouveng,
Gardwell and Low, 1967). We have
determined whether the lymphocytes
from patients with ovarian cancer will
transform when challenged with ovarian
cancer cell extracts and whether there is
any correlation between the extent of
disease and the ability of the lympho-
cytes to transform in vitro.
Much attention has been given to
embryonic antigens in recent years and the
hypothesis that " tumour specific anti-
gens " arere-expressed embryonic ahtigens
has been derived from studies on viral
and chemically induced animal tumours
(Coggin, Ambrose and Anderson, 1970;
Coggin et al., 1971; Baldwin, Glaves and
Vose, 1972). We have therefore also looked
atthe blastogenic response to a cell extract
offoetal ovary to seewhether anoncofoetal
antigen might be at least partly respon-
sible for this blastogenic response.
To assess whether the blastogenic
responses were in any way caused by
normal ovarian constituents in the tumour
or foetal extracts, lymphocytes from
patients in all 3 groups were challenged
with cell extracts from normal ovarian
tissue.
MATERIALS AND METHODS
Tumour and normal ovarian cell extracts
(CE) were obtained by a modified method
AbbreviatiorLs: FCS, FoetalCalf Serum; AS,Autologous Serum; CE, CellExtract, ct/min.; S.I. Stimulation
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described by Oren and Herberman (1971).
Approximately 5 g of fresh tumour was dis-
aggregated in 0 14 mol/I sodium chloride
(1 ml/g wet tissue) by high speed homo-
genization, frozen rapidly in liquid nitrogen
and then thawed; finally hypotonic saline
was added. The tumour suspension was
centrifuged at 400 q (4°C) after each of these
procedures, the supernatant fluid from each
stage being pooled and centrifuged at
105,000 g at 4°C for one hour. The protein
content of the resultant supernatant was
estimated by the technique of Lowry,
Rosebrough and Farr (1952).
Preparation of the foetal tissue extracts
was modified slightly. The initial stage was
as described above but in the final stage the
extract was centrifuged at 3000 g at 4°C for
one hour and the resulting supernatant used
to assess blastogenic responses; this modi-
fication was introduced to procure a larger
yield of protein than would have resulted
from iiltracentrifugation.
Lymphocytes were prepared by layering
defibrinated blood over Ficoll/Triosil
(B0yum, 1968) and subsequently resuspend-
ing in Tissue Culture Medium 199 containing
12*5% ofautologous or foetal calfserum, at a
concentration of 106 lymphocytes/ml. Then
100jg of the ovarian cancer, normal ovary
or foetal ovary cell extract (CE) was added
to appropriate tubes containing 1 x 106
lymphocytes, the amount of CE for optimal
blastogenesis being determined by dose-
response assay. Each experiment was per-
formed in duplicate.
The lymphocyte cultures were incubated
for 5 days at 37°C in 5% C02, pulsed with
1 0 UCi 1251 UDR (5 iodo-2 deoxyuridine) for
4 h and harvested by washing twice with
Hanks' medium and once with 10% cold
trichloracetic acid. The 125J UDR incorpo-
ration into the acid insoluble fraction was
then measured by using a Wilj gamma
counter.
Lymphocyte responses in 48 patients
with ovarian cancer, 18 females with other
cancers in remission from disease and 26
controls were challenged with CE from
serous papillary cystadenocarcinoma of the
ovary. The controls were normal non-
pregnant females aged between 32 and 74
years, mostly awaiting elective surgery for
prolapse.
Eighteen of the patients with ovarian
cancer, 13 with other cancers and 13 controls
were tested for responses to foetal ovary; in
these patients blastogenic responses to foetal
liver or lung (from the same foetus) were also
assessed to evaluate the possibility of trans-
plantation allo-antigenic responses.
Responses to normal ovarian extracts
were assessed in 11 of the ovarian cancer
patients, 7 normal controls and 8 patients
with other cancers, to determine whether any
responses to ovarian cancer or ovarian foetal
extracts could be attributed to sensitization
to normal tissue determinants.
No patients had had any chemotherapy
or radiotherapy for at least 2 months before
these tests were performed, and none of the
allogeneic tests were conducted on patients
who had received a blood transfusion for at
least 6 months before the test was carried out.
RESULTS
Dose response assays for ovarian cancer
cell extract (CE)
1 X 106 lymphocytes were stimulated
with doses of CE varying between 50 and
200 /tg wherever this was possible (Fig. 1).
From the data obtained we calculated
that the optimal dose for blastogenic
stimulation was generally 100 ,ug.
Blastogenic responses
The blastogenic responses to 100 HgCE
for patients with ovarian cancer both
in remission and relapse and for patients
with other cancers are shown in Fig. 2, the
response being expressed for each patient
as the et/min difference between stimul-
ated and unstimulated lymphocytes.
These data are further subdivided into
ct/min differences for lymphocytes in-
cubated in FCS or AS. A stimulatory
effect was recorded above the zero line, an
inhibitory effect below it. Responses to
normal ovarian cell extract are also
shown on these graphs. The means of
difference between stimulated and un-
stimulated responses are shown at the
bottom of Fig. 2.
The blastogenic responses to 100 jugCE
for patients with ovarian cancer in
remission are shown in Table I, these
responses being expressed as the stimul-
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FIG. I -Blastogenic respoinses to varying doses of ovarian cancer cell extracts.
ation index. Responses to autologous
extracts and responses from patients with
endometrioid cancer of the ovary are also
shown in this Table.
The x2 and P values for responses in
the 3 groups of patients compared with
normal controls are shown in Table II.
Significant differences were found
between the response of ovarian cancer
remission patients and the normal
controls in both AS and FCS (P < 0 01);
there was no significant difference be-
tween the response of ovarian cancer
relapse patients and the normal controls.
The percentage error between any two
measurements of the same response was
approximately 120%.
Figure 3 records the ct/min differences
for the blastogenic responses to foetal
ovarian and other foetal tissue (lung or
liver). The means of the difference
between stimulated and unstimulated
responses are shown at the bottom of this
graph.
A response to foetal ovary extract was
present in the ovarian cancer group which
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BLASTOGENIC RESPONSE TO 1009g OVARIAN CANCER C.E. AND NORMAL OVARY.
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FIG. 2.-Comparison of blastogenic responses to ovarian cancer CE in ovarian cancer remission and relapse
patients, normal controls and female patients with other cancers.
was not present in the control group.
Although there was no great difference in
response to the extract between the
ovarian cancer group and patients with
other cancers, responses in ovarian cancer
groups were higher and occurred in more
patients.
There was no significant difference in
response to ovarian cancer extract com-
pared with the response to normal adult
ovary or foetal ovary in any groups.
DISCUSSION
Evidence for both " tumour associ-
ated " and " tumour specific " antigens in
ovarian cancer has been claimed by other
workers (Levi, Keller and Mandl, 1969;
Hellstrom et al., 1971; Di Saia et al., 1971;
Bhattacharya and Barlow, 1973; Knaupf
and Urbach, 1974). However, from our
data it would appear that the antigenic
determinants present in ovarian cancer
are really rather complex.
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TABLE I.-Blastogenic Response of Ovarian Cancer Patients in Remission to Ovarian
Tumour Cell Extract
AS
Stimulated
Unstimulated 100 ,zg CE
(ct/min) (et/min)
*10350 23280
*3521 3735
*1890 2400
*5940 9025
*2340 2670
*4095 5790
*3120 3210
t7020 7500
t3000 4000
t7200 13080
t2350 2601
4480 4200
2430 3840
4320 2870
3240 4950
3510 2700
3300 4680
2010 1800
2480 2840
6940 7400
1320 2700
2100 3120
2340 2070
2760 3300
2640 2070
FCS
, M _ \~~~~~~~~~~~~~~~~~~.
Unstimulated
(ct/min)
9870
3315
2050
1380
1560
2850
6060
2900
9240
2520
3020
3570
3000
2200
2250
2280
1740
3100
6060
1530
1740
990
3630
4460
* Autologous CE.
t Endometrioid carcinoma of the ovary stimulated
Stimulated
lOO,ug CE
(ct/min)
9420
3651
4440
1890
3960
3840
8940
8000
17100
4260
2540
2040
4301
2640
2640
4440
2310
2700
8940
1380
3180
2640
4260
4980
Stimulation Index
(stimulated/unstimulated)
AS FCS
2-2 1-0
1-1 1-1
1-3 2-2
1-5
1.1 1-4
1.5 2-5
1-0 1-3
1.1 1.5
1-4 3-1
1-9 1-8
1.1 1-7
0 9 0-8
1-6 0-6
0 7 1-4
1-5 1 2
0-8 1-2
1-4 2-0
0 9 1-3
1-2 0-9
1-0 1.5
2-0 0 9
1.5 1-8
0 9 2-7
2-2
1-2
0-8 1.1
by serous papillary cystadenocarcinoma CE.
TABLE II.-To show X2 and Probability Levels, Comparing Ovarian Cancer Patients and
Other Cancer Patients with Normal Controls in AS and FCS
OV Ca remission
AS FCS
Normal x2 = 9 - 818 P = 11-289
Controls P = 0 007 P= 0 003
OV Ca relapse
AS FCS
x2= 8 70 x2= 4-791
P= 0-6 P= 0-09
Other cancers
AS FCS
x2= 5-176 x2= 1-976
P 0-08 P = 03
The blastogenic response to ovarian
cancer extract shows that ovarian cancer
patients in remission are sensitized to a
determinant (s) in the extract when
normal controls are not. While some of
the patients with progressive disease are
also sensitized to the determinants, the
responses in this group are not signi-
ficantly different from the controls.
Incubating lymphocytes in FCS only
marginally improved responses in the
relapse group of patients.
The impaired blastogenic response to
CE in relapse patients may reflect a
general impairment in the ability of
lymphocytes from these patients to trans-
form to any appropriate antigenic
stimulus. Impaired cell mediated im-
munity has been demonstrated in vivo
by delayed skin hypersensitivity tests in
patients with ovarian cancer who are in
relapse (Khoo and Mackay, 1974). In
vitro lymphocyte impairment has been
demonstrated in non-lymphoid tumours
by Catalona, Sample and Chretien (1973).
However, Di Saia et al. (1971) demon-
strated in vitro lymphocyte cytoxicity on
ovarian cancer cells from relapse patients
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BLASTOGENIC RESPONSE TO FOETAL OVARY ( and Foetal Lung or Liver )
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FIG. 3.-Comparison of blastogenic responses to foetal ovary and foetal lung or liver CE
patients, normal controls and female patients with other cancers.
in ovarian cancer
when the lymphocytes were incubated in group, and the fact that transformation
FCS. to autologous CE occurred in 6 of 11
In experiments where allogeneic CE patients, suggests that HLA does not
was used, histocompatibility (HLA) anti- contribute to the blastogenic response in
gen could have induced transformation, this system. This is consistent with the
but the fact that there was no significant findings of Mavligit et at. (1973) and
transformation to the CE in the control Gutterman et at. (1972) who have found
0
0
0
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that solubilized antigens stimulate in
vitro blastogenesis only ifthe lymphocytes
have been sensitized to the antigen in vivo.
The tendency for lymphocytes from
patients with endometrioid ovarian cancer
to transform when challenged with CE of
serous papillary carcinoma requires
further consideration. If the response is
due to a tumour specific antigen this
would suggest that the antigen is possibly
organ-specific and this could include
sensitization to normal ovarian deter-
minants.
The ovarian tumours dealt with in this
paper share a common embryological
origin and the possibility that an onco-
foetal antigen was responsible for the
organ specific responses therefore promp-
ted us to investigate this aspect further.
This idea has been substantiated to some
extent by the blastogenic response to
ovarian foetal ovary extract and has not
hitherto been reported. From our data,
the response to foetal ovary appears to be
tumour associated, although the responses
are greater in the ovarian cancer patients.
In view of the fact that we have also
demonstrated blastogenic responses to
normal ovarian cell extract, the existence
of ovarian cancer oncofoetal antigens
should be regarded with some reserve
until determinants in normal adult ovary
responsible for blastogenesis can be exclu-
ded from a purified extract offoetal ovary.
A cell mediated response to normal
breast tissue has been demonstrated in
patients with breast cancer (Alford,
Hollinshead and Herberman, 1973) and to
normal lung tissue in patients with lung
cancer (Hollinshead, Stewart and Herber-
man, 1974). It appears that the same
holds true for ovarian cancer patients in
their response to normal ovary extracts.
This would fit in with the postulate that
exposure to normal cell constituents by a
break down of the basement membrane in
tumours can sensitize the cancer patients
to these normal cell products (Hall, 1974).
Antigens which could be responsible for
the blastogenic effect of normal ovarian
extract include normal tissue antigen
described by Dickinson et al. (1974) and
oncofoetal antigens which may occur in
normal tissue (Burtin, 1974). More
sophisticated methods are required to
detect an autoimmune element in the host
response to tumour and we are investi-
gating this possibility further.
Conclusion
Patients with ovarian cancer in re-
mission have a blastogenic response to
autologous and allogeneic ovarian cancer
cell extract which is significantly greater
than in control patients. The response is
reduced in relapse patients. This implies
sensitization to a determinant (s) in the
extract which is not demonstrable in
relapse; incubating the lymphocytes in
FCS only marginally improves the res-
ponse. Although the major response has
been in patients with ovarian cancer, it
does not appear to be specific to these
tumours. Our work suggests that there
are determinants which are shared by
ovarian tumours of different histology but
of the same postulated embryological
origin; since we have demonstrated a
blastogenic response to foetal ovary
extract, these shared antigens may be
oncofoetal. Nevertheless, because we
have also demonstrated blastogenic res-
ponses to normal ovary, it will be neces-
sary to eliminate the determinants
responsible for this before the exact
nature of any " tumour associated"
antigen can be established.
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